Rhumbline Advisers Curis Inc Transaction History

Rhumbline Advisers

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 08, 2023	BUY	$0.57 - $0.99 $1,642 - $2,853	2,882 New	2,882 $2,000
Q2 2022 Aug 11, 2022	SELL	$0.71 - $2.43 $64,990 - $222,432	-91,536 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$2.31 - $5.13 $11,429 - $25,383	4,948 Added 5.71%	91,536 $218,000
Q4 2021 Feb 10, 2022	SELL	$4.45 - $8.09 $8,268 - $15,031	-1,858 Reduced 2.1%	86,588 $412,000
Q3 2021 Nov 12, 2021	BUY	$6.94 - $8.85 $35,560 - $45,347	5,124 Added 6.15%	88,446 $693,000
Q2 2021 Aug 05, 2021	BUY	$7.45 - $16.27 $620,748 - $1.36 Million	83,322 New	83,322 $672,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.